We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. announced that the FDA has granted Fast Track designation to its adrenergic receptor antagonist, ADP418, for treating decompensated heart failure (“DHF”). The company initiated a phase I study to evaluate ADP418 in DHF patients in the fourth quarter of 2019.
Shares of Arena have increased 7.2% in the past year against the industry’s decrease of 2.8%.
The company’s pipeline currently consists of two key candidates, namely etrasimod (autoimmune diseases) and olorinab (pain and fibrotic diseases).
A pivotal phase III study – ELEVATE UC 52 – is evaluating etrasimod in patients with moderately-to-severely active ulcerative colitis. The phase IIb ADVISE study is evaluating the candidate atopic dermatitis patients. The company recently initiated the phase IIb/III CULTIVATE study for treating patients with Crohn's disease. It also plans to initiate two new mid-stage studies, which will evaluate etrasimod in eosinophilic esophagitis, an inflammatory gastrointestinal condition, and alopecia areata, an autoimmune disorder causing hair loss.
A phase II CAPTIVATE study is evaluating olonarib as a treatment for abdominal pain associated with irritable bowel syndrome.
The company expects study data readouts from these mid and late-stage studies in 2020 and 2021.
The company is also focusing on expanding its pipeline. It plans to file a new investigational new drug application every year over the next five years to support initiation of clinical studies on new candidates or indications. Earlier this month, it entered into a strategic multi-year partnership with privately-held Beacon Discovery. Per the terms of the deal, while Beacon will be responsible for drug discovery using its proprietary GPCR discovery platform, Arena will develop and commercialize promising novel compounds as a treatment for a variety of immune and inflammatory diseases.
Meanwhile, Arena has announced that it will form a new subsidiary, Arena Neuroscience. The subsidiary will focus on programs and platforms to develop therapies targeting neuroinflammation indications.
We would like to remind investors that in January 2019, Arena out-licensed the global rights to its pulmonary arterial hypertension candidate ralinepag to United Therapeutics (UTHR - Free Report) . The deal significantly boosted Arena’s cash resources.
Coherus’ earnings estimates increased from $1.50 to $1.67 for 2020 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average beat being 149.94%. Shares of the company have gained 69.5% in the past year.
Anavex’s loss estimates have narrowed from 67 cents to 42 cents for 2020 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, the average beat being 0.57%. Share price of the company has increased 74.1% in the past year.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
Arena Pharmaceuticals, Inc. announced that the FDA has granted Fast Track designation to its adrenergic receptor antagonist, ADP418, for treating decompensated heart failure (“DHF”). The company initiated a phase I study to evaluate ADP418 in DHF patients in the fourth quarter of 2019.
Shares of Arena have increased 7.2% in the past year against the industry’s decrease of 2.8%.
The company’s pipeline currently consists of two key candidates, namely etrasimod (autoimmune diseases) and olorinab (pain and fibrotic diseases).
A pivotal phase III study – ELEVATE UC 52 – is evaluating etrasimod in patients with moderately-to-severely active ulcerative colitis. The phase IIb ADVISE study is evaluating the candidate atopic dermatitis patients. The company recently initiated the phase IIb/III CULTIVATE study for treating patients with Crohn's disease. It also plans to initiate two new mid-stage studies, which will evaluate etrasimod in eosinophilic esophagitis, an inflammatory gastrointestinal condition, and alopecia areata, an autoimmune disorder causing hair loss.
A phase II CAPTIVATE study is evaluating olonarib as a treatment for abdominal pain associated with irritable bowel syndrome.
The company expects study data readouts from these mid and late-stage studies in 2020 and 2021.
The company is also focusing on expanding its pipeline. It plans to file a new investigational new drug application every year over the next five years to support initiation of clinical studies on new candidates or indications. Earlier this month, it entered into a strategic multi-year partnership with privately-held Beacon Discovery. Per the terms of the deal, while Beacon will be responsible for drug discovery using its proprietary GPCR discovery platform, Arena will develop and commercialize promising novel compounds as a treatment for a variety of immune and inflammatory diseases.
Meanwhile, Arena has announced that it will form a new subsidiary, Arena Neuroscience. The subsidiary will focus on programs and platforms to develop therapies targeting neuroinflammation indications.
We would like to remind investors that in January 2019, Arena out-licensed the global rights to its pulmonary arterial hypertension candidate ralinepag to United Therapeutics (UTHR - Free Report) . The deal significantly boosted Arena’s cash resources.
Achillion Pharmaceuticals, Inc. Price
Achillion Pharmaceuticals, Inc. price | Achillion Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Arena currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks to consider from the biotech sector are Coherus BioSciences, Inc. (CHRS - Free Report) and Anavex Life Sciences Corp. (AVXL - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Coherus’ earnings estimates increased from $1.50 to $1.67 for 2020 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average beat being 149.94%. Shares of the company have gained 69.5% in the past year.
Anavex’s loss estimates have narrowed from 67 cents to 42 cents for 2020 over the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, the average beat being 0.57%. Share price of the company has increased 74.1% in the past year.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>